Immunoprecise Cost Of Revenue from 2010 to 2024

IPA Stock  USD 0.38  0.03  8.57%   
Immunoprecise Antibodies' Cost Of Revenue is increasing over the years with slightly volatile fluctuation. Overall, Cost Of Revenue is expected to go to about 13.1 M this year. From 2010 to 2024 Immunoprecise Antibodies Cost Of Revenue quarterly data regression line had arithmetic mean of  4,459,389 and r-squared of  0.89. View All Fundamentals
 
Cost Of Revenue  
First Reported
2015-07-31
Previous Quarter
3.4 M
Current Value
2.9 M
Quarterly Volatility
968.4 K
 
Yuan Drop
 
Covid
Check Immunoprecise Antibodies financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Immunoprecise Antibodies' main balance sheet or income statement drivers, such as Depreciation And Amortization of 6 M, Interest Expense of 18.1 K or Total Revenue of 25.7 M, as well as many indicators such as Price To Sales Ratio of 0.11, Dividend Yield of 0.87 or Days Sales Outstanding of 0.41. Immunoprecise financial statements analysis is a perfect complement when working with Immunoprecise Antibodies Valuation or Volatility modules.
  
Check out the analysis of Immunoprecise Antibodies Correlation against competitors.
For information on how to trade Immunoprecise Stock refer to our How to Trade Immunoprecise Stock guide.

Latest Immunoprecise Antibodies' Cost Of Revenue Growth Pattern

Below is the plot of the Cost Of Revenue of Immunoprecise Antibodies over the last few years. Cost of Revenue is found on Immunoprecise Antibodies income statement and represents the costs associated with goods and services Immunoprecise Antibodies provides. Indirect cost, such as salaries, is not included. In other words, cost of revenue is the total cost incurred to obtain a sale. It is more than the traditional cost of goods sold, since it includes specific selling and marketing activities. It is Immunoprecise Antibodies' Cost Of Revenue historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Immunoprecise Antibodies' overall financial position and show how it may be relating to other accounts over time.
Cost Of Revenue10 Years Trend
Slightly volatile
   Cost Of Revenue   
       Timeline  

Immunoprecise Cost Of Revenue Regression Statistics

Arithmetic Mean4,459,389
Geometric Mean1,732,998
Coefficient Of Variation103.97
Mean Deviation3,980,014
Median2,990,323
Standard Deviation4,636,434
Sample Variance21.5T
Range12.8M
R-Value0.94
Mean Square Error2.6T
R-Squared0.89
Slope977,870
Total Sum of Squares301T

Immunoprecise Cost Of Revenue History

202413.1 M
202312.5 M
20229.1 M
20218.4 M
20206.4 M
2019M
20185.6 M

About Immunoprecise Antibodies Financial Statements

Immunoprecise Antibodies stakeholders use historical fundamental indicators, such as Immunoprecise Antibodies' Cost Of Revenue, to determine how well the company is positioned to perform in the future. Although Immunoprecise Antibodies investors may analyze each financial statement separately, they are all interrelated. For example, changes in Immunoprecise Antibodies' assets and liabilities are reflected in the revenues and expenses on Immunoprecise Antibodies' income statement, which ultimately affect the company's gains or losses. Understanding these patterns can help in making the right long-term investment decisions in Immunoprecise Antibodies. Please read more on our technical analysis and fundamental analysis pages.
Last ReportedProjected for Next Year
Cost Of Revenue12.5 M13.1 M

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.
When determining whether Immunoprecise Antibodies offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Immunoprecise Antibodies' financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Immunoprecise Antibodies Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Immunoprecise Antibodies Stock:
Check out the analysis of Immunoprecise Antibodies Correlation against competitors.
For information on how to trade Immunoprecise Stock refer to our How to Trade Immunoprecise Stock guide.
You can also try the Headlines Timeline module to stay connected to all market stories and filter out noise. Drill down to analyze hype elasticity.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Immunoprecise Antibodies. If investors know Immunoprecise will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Immunoprecise Antibodies listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share
(0.77)
Revenue Per Share
0.921
Quarterly Revenue Growth
(0.07)
Return On Assets
(0.13)
Return On Equity
(0.64)
The market value of Immunoprecise Antibodies is measured differently than its book value, which is the value of Immunoprecise that is recorded on the company's balance sheet. Investors also form their own opinion of Immunoprecise Antibodies' value that differs from its market value or its book value, called intrinsic value, which is Immunoprecise Antibodies' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Immunoprecise Antibodies' market value can be influenced by many factors that don't directly affect Immunoprecise Antibodies' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Immunoprecise Antibodies' value and its price as these two are different measures arrived at by different means. Investors typically determine if Immunoprecise Antibodies is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Immunoprecise Antibodies' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.